This move is archived. Current quotes and coverage live on the stock page.
Follow HBP
Helix BioPharma Corp. has seen a significant drop in its stock price, raising concerns among investors.
Helix BioPharma Corp. (HBP.TO) is experiencing a notable decline in its stock price, down 7.22% today, closing at CA$1.67. This drop comes amid limited news and uncertainty about the company's future prospects.
Investor takeaway: Investors should remain cautious as Helix BioPharma's stock struggles to maintain momentum, reflecting broader market concerns and the company's ongoing challenges.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$70.27M
52W high
$3.00
52W low
$0.85
1W change
-3.16%
Beta
-0.14
Analyst Price Targets
Based on analyst covering HBP · as of Sep 17, 2026
Wall Street analysts forecast HBP stock price to rise 171.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+171.7% Upside
Current Price
C$0.92
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
109.6%
Annualized
90-Day Vol
76.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.77
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.87 | C$0.59 – C$1.27 |
| 60 trading days | C$0.82 | C$0.48 – C$1.39 |
| 90 trading days | C$0.77 | C$0.40 – C$1.48 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
If Helix BioPharma can effectively navigate its clinical development phase and make the most of its recent executive appointments, it may regain investor confidence and stabilize its stock price.
Bear case
Continued weakness in stock performance could signal deeper issues within the company or negative market sentiment, potentially leading to further declines if no positive developments occur.
Stock Performance Overview
Helix BioPharma Corp.'s stock has fallen significantly today, down 7.22% to CA$1.67. This decline raises questions about investor confidence and the company's strategic direction, especially considering recent leadership changes.
Advertisement
Market Sentiment and Future Outlook
The drop in Helix BioPharma's stock price may reflect broader market concerns about the company's ability to execute its clinical development strategy. With no recent major announcements or financial results to boost investor confidence, the outlook remains uncertain.
Recent Developments
While Helix BioPharma appointed a new Chief Medical Officer and made changes to its board, these developments have not yet resulted in positive sentiment among investors. The market seems to be waiting for tangible results from these changes before reassessing the stock.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
